GLP-1glp-1 receptor agoniststhyroiditistype 2 diabetestrinetx

GLP-1 users show 26% higher autoimmune thyroiditis risk versus DPP-4 inhibitors

In a TriNetX target-trial emulation of 107,912 matched pairs, thyroid malignancy risk did not differ between the two drug classes.

By Maren Holt · Senior Reporter, GLP-1

Oct 1 20:00 ETSource: International journal of medical sciences

The wire

01Autoimmune thyroiditis was newly recorded in 524 GLP-1 receptor agonist initiators (0.49%) versus 417 DPP-4 inhibitor initiators (0.39%), giving a hazard ratio of 1.26 (95% CI 1.11-1.43) over up to four years.
02Modestly higher risks also appeared for nontoxic uninodular (HR 1.07) and multinodular goiter (HR 1.11), which may inform thyroid monitoring conversations in type 2 diabetes.
03Absolute differences were small and the authors cite possible residual confounding and surveillance bias; thyroid malignancy risk was not elevated (HR 0.93) and findings need validation.

From the source

Association of GLP-1 Receptor Agonist Use with Thyroid Outcomes in Adults with Type 2 Diabetes
International journal of medical sciences · 2026 · Hsiao CC, Tsai MH, Jhu JY et al.

Read at pubmed.ncbi.nlm.nih.gov

Source URL https://pubmed.ncbi.nlm.nih.gov/42910111/